AREC — Arecor Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- £14.35m
- £11.32m
- £5.05m
Annual cashflow statement for Arecor Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.51 | -6.95 | -10.5 | -8.9 | -10.6 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.445 | 0.985 | 0.346 | 0.388 | 3.28 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.04 | 0.339 | -0.925 | 2.18 | -2.26 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1.86 | -5.45 | -10.8 | -5.84 | -9.15 |
| Capital Expenditures | -0.052 | -0.069 | -0.345 | -0.151 | -0.023 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.003 | 0.001 | -7.65 | 6.67 | 1.74 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.049 | -0.068 | -7.99 | 6.52 | 1.72 |
| Financing Cash Flow Items | -0.083 | -1.46 | -0.38 | -0.015 | -0.659 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.77 | 20.9 | 5.16 | -0.18 | 5.65 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.175 | 15.4 | -13.6 | 0.328 | -1.85 |